Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with type 2 diabetes and obesity or overweight and adults with severe obesity and established cardiovascular disease, and the timeline for future readouts, presentations and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations
Over time, these features may save you money
PMID: 10963046
Sources: Conlon MA, Tomas FM, Owens PC, et al
Reversibility: The oral medication has a shorter half-life than the injectable
Can clinical factors estimate insulin resistance in type 1 diabetes
US$ 22.07
US$ 22.01
.webp)
US$ 28.67
US$ 26.18
US$ 28.62
